INT15744
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
This absence of a zero hour effect suggests that rebound does not occur during eccentric dosing with immediate-release IS-5-MN. | |||||||||||||||
| |||||||||||||||
|
We conducted a controlled double-blind trial comparing the effects of isosorbide-5-mononitrate (IS-5-MN) 3 X 20 mg, sustained release IS-5-MN 50 mg once daily and sustained release nifedipine 3 X 20 mg in patients with documented coronary heart disease and transient ischaemic episodes. 20 patients were included, 15 finished the four-week study period. | |||||||||||||||
| |||||||||||||||
|
In a double-blind, randomized cross-over study the antianginal efficacy and tolerability of Elantan Long (50 mg sustained-release IS-5-MN) were compared with a 80-mg sustained-release (s.r.) | |||||||||||||||
| |||||||||||||||
|
Sustained-release IS-5-MN in the treatment of coronary heart disease. | |||||||||||||||
| |||||||||||||||
|
To determine whether nitration was related to the decline of Mn-SOD activity in the SO group, Mn-SOD nitration was evaluated following immuno-precipitation of Mn-SOD. | |||||||||||||||
| |||||||||||||||
|
Inefficient targeting of Mn-SOD may leave mitochondria inabequately defended against superoxide radicals. | |||||||||||||||
| |||||||||||||||
|
This finding is likely because Mn is excreted in the bile, and in persons with chronic liver disease, the excretion of Mn is markedly impaired, with subsequent accumulation in the brain. | |||||||||||||||
| |||||||||||||||
|
Importantly, for patients with liver disease, the hyperintensive T1-weighted MRI signal in the basal ganglia is normalized after liver transplantation (Aggarwal et al. 2006) that corrects the impairment in Mn excretion. | |||||||||||||||
| |||||||||||||||
|
This finding is likely because Mn is excreted in the bile, and in persons with chronic liver disease, the excretion of Mn is markedly impaired, with subsequent accumulation in the brain. | |||||||||||||||
| |||||||||||||||
|
Once-a-day therapy with a slow-release formulation of IS-5MN is used widely in Europe for 24-hour prophylaxis of angina pectoris. | |||||||||||||||
| |||||||||||||||
|
Two hours after administration of 100 mg sustained-release IS-5-MN, mean resting pulmonary artery pressure (PAP), measured with a Swan-Ganz catheter, was reduced by 32% (p less than 0.001) and at submaximal exercise level (50 W, 3 min) by 37% (p less than 0.001). | |||||||||||||||
| |||||||||||||||
|
At the end of 1 week of therapy with sustained-release IS-5-MN a slight, clinically irrelevant reduction of hemodynamic effect was recorded. | |||||||||||||||
| |||||||||||||||
|
The possibility of maintaining preload reduction and enhancement of exercise tolerance during an interval treatment with 100 mg/day of slow-release isosorbide-5-mononitrate (IS-5-MN) was investigated in 12 patients (aged 57 +/- 5.0 years) with angiographically confirmed coronary artery disease and chronic stable angina pectoris. | |||||||||||||||
| |||||||||||||||
|
However, SDS-PAGE and Western blot analysis of lysates from cells transfected with wt or p.Glu252Lys A-domain revealed that non-reduced samples contained a mixture of both forms of A-domain in approximately equal quantities (Fig. 2B; lanes 2 and 3), which is characteristic of a cell expressing high levels of recombinant protein that is actively being folded and secreted. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.